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ABSTRACT 
Objective: The objective of the work was to formulate coated microbeads using core-coat technique for chronotherapeutic delivery of Carvedilol (cd). 
Methods: Sodium alginate microbeads containing cd was formulated by ionic gelation method using calcium chloride as a gelling agent. Microbeads 
were then coated with acrylcoat L 100 (acL 100), acrylcoat S 100 (acS 100), ethyl cellulose (EC), and acrylcoat E30 D (acE 30D) in different ratio. 
Formulated batches were evaluated using FTIR, particle size measurement, percent entrapment efficiency, micrometric properties, swelling studies, 
loose surface crystal studies, percentage moisture loss. The formulations were then subjected to in vitro dissolution studies. Cumulative release data 
was then subjected to different dissolution models reported in the literature. 
Results: Formulated batches of microbeads were within acceptable particle size range with good to fair flow properties. Entrapment efficiency was 
in the range of 64% to 99.52%. Loose surface crystal study revealed successful drug entrapment within a range of 2.11 to 9.93%. Swelling studies 
revealed maximum swelling in alkaline phosphate buffer pH 7.4 solution and percentage moisture loss was within 0.24% to 7.55%. SEM showed 
microbeads to be spherical in nature and FTIR study exhibited compatibility among the drug and polymer. In vitro release study was carried out for 
first 3 h in 0.1N HCl and subsequently for 7 h in phosphate buffer solution pH 7.4. Formulation code AC3, AC4, LA4 and LA6 were found in line with 
our objective of chronotherapeutic drug delivery. 
Conclusion: Sodium alginate beads loaded with cd and coated with different ratios of coating solutions were successfully formulated and evaluated 
to optimize the best possible combinations of the coat-core ratio for chronotherapeutic delivery. 
Keywords: Chronotherapeutic drug delivery, Carvedilol, Core-coat technique, Microbeads 




With the expansion of biopharmaceutics and pharmacokinetics 
knowledge, many new drug delivery systems have been introduced 
over the last 25 y including controlled, sustained, and prolonged drug 
delivery systems. One of the newer drug delivery systems which have 
attracted many researchers is based on the concept of 
chronotherapeutic which can deliver the drug when it is mostly 
needed [1, 2]. Chronotherapeutic drug delivery is the one that delivers 
the drug molecule in a rapid and transient manner within a short time 
period immediately after a predetermined lag period [3]. The rationale 
for the use of this system for our work was to deliver drug at a time 
when the disease condition is in the most morbid and mortal state 
during one circadian cycle of 24 h. Particular rhythmic onset of 
symptoms is regularly observed in diseases like asthma, ulcers, 
diabetic conditions, hypertension, myocardial infraction, angina 
pectoris and cardiac attacks and sometimes in attention deficit 
syndrome and many others [4]. Several chronotherapeutic release 
formulation have been developed recently wherein tablets and 
capsules are the dosage form developed to release the drug after a lag 
time period for the match the circadian cycle of the disease [5]. The 
symptoms of hypertension are pronounced predominantly during the 
early hours of the morning as renin angiotensin–aldosterone system is 
activated in the morning and therefore blood pressure rises rapidly, 
and this rise in blood pressure has been associated with increased risk 
of cardiovascular events such as stroke and myocardial infarction [6]. 
Thus treatment of such disease occurring in the early hours is not 
convenient using the existing conventional marketed tablets and 
capsules [7]. Hence, a newer dosage form which can release the drug 
after a lag time causing a maximum concentration of drug in plasma to 
match the symptom of the disease when it is worse to fatal may help to 
minimize the rate of such attacks and death [8]. The other advantages 
of chronotherapeutic drug delivery systems include convenience, 
reduced dosing frequency, decreased fast pass metabolism, reduced 
tolerance as exposure to drug is not constant like conventional dosage 
forms, reduced toxicity and decreased total required therapeutic or 
instantaneous preventive drug dose level matching exactly the 
biological and physiological needs to treat the disease at each point in 
time. Ultimately, all these lead to improved patient compliance. cd, an 
antihypertensive drug was used as a model for this work as it is widely 
used for reducing hypertension, chronic heart failure, angina pectoris 
and kidney problems etc. Also the fact that no chronotherapeutic 
dosage form of cd is available in the market with reference to above 
mentioned conditions which needs the drug at its peak (Cmax) during 
early hours of morning though immediate release and controlled 
released formulations are available from long time. This had made us 
to take up this drug for the preparation and evaluation of coated 
microbeads of cd for chronotherapeutic delivery which will release the 
dug after a lag time causing a maximum concentration of drug in 
plasma to match the symptom of the disease when it is worse to fatal. 
MATERIALS AND METHODS 
Materials 
CD was obtained as a gift sample from Mylan Laboratories, Hyderabad. 
Sodium alginate, EC, acL 100, acS 100, acE 30D and calcium chloride 
was purchased from SD Fine chem., Mumbai. All other chemicals and 
reagents used were of analytical grade. 
Methods 
Preparation of CD micro beads by ionic gelation method  
The weighted quantity of sodium alginate was dissolved slowly  in 
100 ml of deionized water in a beaker using a mechanical stirrer 
untill all the alginates dissolves to give a viscous solution. In this 
solution, cd was added with constant stirring to get a dispersion of 
water-insoluble drug. This mixture is then taken in a syringe fitted 
with a needle of 21 gauges and drop by drop poured in a 250 ml 
calcium chloride solution (10% w/v) to obtain the beads by ionic 
exchange mechanism. After the formation of the beads, these were 
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kept in calcium chloride solution for two hour time for complete 
ionic exchange, to get nearly spherical rigid microbeads. Microbeads 
were then washed several times with distilled water and dried at 40 
°C for 12 h for complete drying [9, 10].  
Fourier transformed infrared spectroscopy  
IR spectroscopy was performed on Fourier transformed infrared 
spectrophotometer (840, Shimadzu, Japan) to ascertain the 
compatibility between sodium alginate and cd. The pellets of cd, 
micro-beads prepared, and potassium bromide was prepared by 
compressing the powders at 20 psi for 10 min on KBr-press and 
measured in the range the spectra were scanned in the wave 
number range of 3000-400 cm-1[11]. 
Coating of microbeads 
Microbeads prepared with sodium alginate and drug by ionic gelation 
technique was coated with a rate controlling polymers namely acL100, 
acS 100, and EC, acE30 D and their combination in different ratios as 
given table 1. Coating solutions were prepared using acetone and 
ethanol in 2:1 ratio. 4 % acL100 and 15 % acS 100 solutions were first 
prepared using coating powders. These solutions were then mixed in 
different ratios viz 1:1, 1:2, 1:3, 2:1 and 3:1. EC was dissolved in a 
mixture of acetone and ethanol 2:1. acE 30D solution was used in the 
range of 0.4 to 0.7% as given in the references of the manufacturer. Dip 
coating technique was employed for coating of all microbeads and 
then left to air dry for 24 h and then dried in a hot air oven, packed and 
stored in self-sealable plastic packets until further use [12].  
Evaluation of microbeads 
Particle size measurement study  
Particle size analysis was done by sieving method using Indian 
Standard sieves ≠ 10, 12, 16, 20, 22, 40, 44. Average particle size was 
calculated using the formula d avg =Σdn/Σn where n is frequency 
weight and d is the mean diameter [13]. 
Scanning electron microscopy (SEM) 
Scanning electron microscopy (Stereo scan S250 MK III, Cambridge, 
UK) was carried out to study the morphological characteristics of cd 
microbeads. Dried microbeads were coated with gold (100A °) under 
an argon atmosphere in a gold coating unit and scanning electron 
micrographs of both higher and lower resolutions were observed [14].  
Drug content estimation and drug entrapment efficiency (DEE %) 
For drug content estimation accurately weighed the amount of 
microbeads equivalent to 100 mg of cd, was suspended in 50 ml of 
methanol to dissolve the polymer as well as the polymer coat. The 
drug was extracted with 50 ml of methanol in separating funnel and 
analyzed by using UV-Visible spectrophotometer (UV-1700, 
Shimadzu, Japan) after suitable dilution. The total drug content was 
determined by employing absorbance obtained in the linear 
regression equation of the calibration curve. The entire test was 
performed in triplicate [15, 16].  
Entrapment efficiency of the microbeads was calculated by using the 
formula 
100/)(Pr% XloadingdruglTheoriticacontentDrugloadingdrugacticalDEE =  
Micromeritic studies  
Flow of microbeads was investigated by determining the angle of 
repose, bulk density, Carr’s index and Hausners ratio. The angle of 
repose was determined by fixed funnel method. Microbeads were 
tapped using bulk density apparatus (Electro lab) for 300 taps in a 
cylinder and the change in volume was measured. Carr’s index and 
Hausner ratio were calculated by the formula 
DfXDDfCarrsIndex /]100)0[((%) −= and 0/ DDfioHausnerRat = , 
where, Df is tapped density; D0 is poured density. All the 
experimental units were studied in triplicate (n=3) [17]. 
Loose surface crystal study 
Loose surface crystal study was done to observe the excess drug present 
on the surface of microbeads. From each batch, 100 mg of microbeads 
was shaken in 100 ml of 0.1N HCl solution for 5 min in a volumetric flask 
and then filtered through Whitman filter paper 41. The amount of drug 
in the filtrate was determined spectrophotometrically at 241 nm and 
calculated as a percent of total drug content. This estimates the surface 
entrapment of the drug by the microbeads [18]. 
Swelling index 
Each 100 mg of the prepared microbeads were weighted initially 
(W1) and was dipped in glass petridishes containing 05 ml 0.1 N HCl 
and phosphate buffer pH 7.4 solution. After an hour, the beads were 
removed wiped with butter paper, and reweighed (W2). The swelling 
index was calculated as follows [19].  
1001/)21( XWWWSw −=  
Percentage of moisture loss 
The CD loaded microbeads were evaluated for percentage moisture 
loss, which gives an idea of their nature. The weighed amount of 
microbeads (10 G, W1) was initially kept in a desiccator containing 
calcium chloride at 37 °C for 24 h. The final weight (W2) was noted 
when no further change in weight of sample was observed. Finally 
the percent moisture content was determined by Equation 
Percent moisture loss= 100)1/21( XWWW −  
In vitro dissolution studies 
As the microbeads were formulated for chronotherapeutic release of 
the drug mostly in the intestinal region of GIT, therefore before 
entering the intestinal area, these microbeads have to pass through 
the acidic region of the stomach which takes around 3 to 4 h. 
Therefore dissolution studies were conducted on two mediums, 
taking 25 mg equivalent of drug three hours in 0.1N HCl which 
mimics the acidic region of the stomach and gastric transit time and 
subsequently in phosphate buffer pH 7.4 which mimic the intestinal 
alkaline pH for next 7 h. The overall dissolution study was carried 
out for 10 h (Electro lab TDT-08L) and then after suitable dilutions 
analyzed using UV spectroscopy (UV-1700, Shimadzu, Japan) [20]. 
Drug release mechanism and kinetics 
In order to establish the mechanism and kinetics of drug release 
from the microbeads, experimental data obtained from the invitro 
dissolution study was fitted with different kinetic model like zero 
order (%cumulative release vs time), first order (log % cumulative 
amount unabsorbed vs time), Higuchi‘s model (%cumulative release 
vs √t), Korsmeyer and Peppas model (log Mt/M∞ vs log t) etc. 
Korsemeyer’s model is widely used when the release mechanism is 
not well known or when more than one type of release phenomena 
could be involved [21, 22].  
Korsmeyer and Peppas equation: tnKQ .=  
Where Q-is functional drug release in time t  
K–Constant incorporating of structural and geometric characteristics 
of controlled release device. 
n–Diffusional release exponent indicative of release mechanism. 
The n value could be used to characterize different release 
mechanism as per the table below. 
Characterization of drug release mechanism  
“n” value Release mechanism 
n<0.4 Case I anomalous transport 
0.4<n<0.5 Diffusion predominantly 
n=0.5 Fickian diffusion (Higuchi matrix) 
0.5<n>1 Anomalous transport (Non-diffusional release) 
n=1 Case II transport (Ideal zero order release)  
n>1 Super case II transport 
 
RESULTS  
Microbeads loaded with cd were prepared by ionic gelation technique 
using sodium alginate and calcium chloride was nearly spherical and 
rigid in shape and strength. The drug-polymer (sodium alginate) 
compatibility study was performed using FTIR study to ascertain if any 
interaction was there between the drug and polymer (fig. 1). 
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Fig. 1: FTIR spectra of cd and microbeads containing cd 
 
Particle size measurement of cd microbeads  
The average particle size was found to be within a narrow range of 
402.85 to 510.03μm.  
Coating of microbeads  
The microbeads prepared were then coated with a different rate 
controlling coating polymer solutions and their combinations in the 
different ratio as shown in table 1. This was done keeping in mind 
the objective of getting a rate delayed the chronotherapeutic release, 
predominantly to the intestinal part of the GIT. As the concept of the 
current study was not to vary the cd: sodium alginate ratio but to 
vary the ratio of the coating solution to get the desired type of 
release, therefore, this concept was named as a coat-core ratio and 
not a drug-polymer ratio. 
Drug content estimation and drug entrapment efficiency (DEE %) 
The drug content and drug entrapment efficiency of all the coated 
microbeads were determined. The results are summarized in table 2. 
The drug entrapment efficiency of the cd microbeads was found to 
be in the range of 64% to 99.52 %. 
 
Table 1: Microbeads coating parameters using different coating solutions and their combinations 
FC Drug (mg) Coating polymer Ratio of polymers Type of coating 
LA1 CD  acL 100 and acS 100 mixture 1:1 Microbeads 
LA2 CD  Do 1:2 Microbeads 
LA4 CD  Do 1:3 Microbeads 
LA6 CD  Do 2:1 Microbeads 
LA7 CD   Do 3:1 Microbeads 
EA1 CD  ECand  
acL 100 mixture 
1:1 Microbeads 
EA2 CD  Do 1:2 Microbeads 
EA3 CD  Do 1:3 Microbeads 
EA4 CD  Do 3:1 Microbeads 
EA5 CD  Do 2:1 Microbeads 
AC1 CD  acE 30 D 0.4% Microbeads 
AC2 CD  Do 0.5% Microbeads 
AC3 CD  Do 0.6% Microbeads 
AC4 CD  Do 0.7% Microbeads 
(FC=Formulation code) 
 
Table 2: Entrapment efficiency of the microbeads 
FC Practical drug loading (drug content) (mg) Theoretical drug loading (mg) % drug entrapment efficiency 
LA1 2.90±1.20 3.125 92.89±0.88 
LA2 2.89±0.39 3.125 92.76±1.62 
LA4 3.0±0.15 3.125 96.00±0.12 
LA6 2.71±0.12 3.125 86.72±1.62 
LA7 3.03±1.62 3.125 97.14±1.90 
EA1 2.87±0.12 3.125 91.84±0.39 
EA2 3.11±0.28 3.125 99.52±0.15 
EA3 2±0.25 3.125 64.00±1.15 
EA4 2.8±0.93 3.125 89.60±0.93 
EA5 2.7±0.15 3.125 86.40±0.25 
AC1 2.56±0.28 3.125 81.92±0.28 
AC2 2.31±0.93 3.125 73.92±0.19 
AC3 2.8±0.88 3.125 89.60±1.91 
AC4 2.84±0.19 3.125 90.88±2.08 
*All the results are expressed mean±SD (n=3)  
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Micromeritic studies  
The rheological study of the prepared microbeads was performed 
which reflects the physiochemical properties of the microbeads and 
tabulated in table 3. Rheological study revealed angle of repose for 
all the microbeads were within the range of good flowability (<25). 
The bulk density was found in a range of 0.3471 to 0.3890. Carr’s 
indexes of microbeads were excellent except LA7 and AC1 and the 
Hausner’s ratio of almost all formulations was good except LA6, LA 7 
and AC4. 
  
Table 3: Rheological behavior of cd microbeads 
FC Angle of repose(ѳ)* Bulk density (gm/cm3) Carr’s index  Comment Hausner’s ratio  Comment 
LA1 28.14±0.12 0.3711 13.11 Excellent 1.20 Good 
LA2 24.19±0.17 0.3478 10.31 Excellent 1.11 Good 
LA4 29.47±0.20 0.3479 9.42 Excellent 1.14 Good 
LA6 24.71±0.43 0.3254 10.01 Excellent 1.27 Poor 
LA7 27.67±0.37 0.3518 16.21 Good 1.30 Poor 
EA1 27.58±0.39 0.3201 13.41 Excellent 1.19 Good 
EA2 25.84±0.44 0.3348 12.20 Excellent 1.21 Good 
EA3 24.35±0.91 0.3358 11.82 Excellent 1.23 Good 
EA4 28.87±0.94 0.3577 10.63 Excellent 1.26 Poor 
EA5 25.78±0.71 0.3478 09.41 Excellent 1.18 Good 
AC1 27.48±0.57 0.3456 18.11 Good 1.20 Good 
AC2 29.10±0.46 0.3587 13.30 Excellent 1.22 Good 
AC3 28.75±0.58 0.3678 12.76 Excellent 1.24 Good 
AC4 28.50±0.73 0.3741 10.42 Excellent 1.27 Poor 
* All the results are expressed mean±SD (n=3) 
 
Loose surface crystal study 
Loose surface crystal studies lend a hand to estimate the excess 
amount of drug attached on the surface of microbeads after a 
successful drug entrapment. The study was executed with variously 
coated microbeads and the results were presented in fig. 2. The 
percentage of drug content in the surface was found to be within the 
range of 2.11 to 9.938%. 
  
 
Fig. 2: Percentage of cd on the surface of the microbeads (All the values were calculated as mean±standard deviation; n=3) 
 
Swelling Index 
Swelling studies for coated microbeads was performed in two pH 
solutions viz. 0.1N HCl providing an acidic pH 1.2 of stomach and 
phosphate buffer pH 7.4 simulating intestinal alkalinity and the 
results are shown in fig. 3. As seen from the fig. the swelling of the 
microbeads were more in alkaline media than acidic media due to 
the solvation of coat and permeation of alkaline media into the 
microbeads than in acid media. 
 
 
Fig. 3: Swelling index of cd microbeads in 0.1N HCl and phosphate buffer pH 7.4 solution (All the values were calculated as 
mean±standard deviation; n=3)) 
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Percentage of moisture loss 
The percentage moisture loss of the formulated microbeads was 
evaluated and the results are shown in fig 4. Moisture loss was found 
to be in the range of 0.24% to 7.55%. 
 
 
Fig. 4: Percentage moisture loss of cd microbeads (All the values 
were calculated as mean±standard deviation; n=3)) 
 
 
Fig. 5: SEM of cd microbeads under low resolution of X 30 
 
 
Fig. 6: SEM of cd microbeads under high resolution of X 300 
Scanning electron microscopy 
Microbeads formulated were found to be nearly spherical without 
much aggregation, (as revealed in SEM studies), discrete and free-
flowing, which are shown in fig. 5 and fig. 6. 
In vitro drug release and kinetic studies of coated microbeads 
Invitro drug release studies of the coated microbeads were carried 
out for three hours in acidic buffer pH 1.2 using 0.1N HCL and 
subsequently for 7 h in phosphate buffer solution pH 7.4. Since the 
objective of the current work was to formulate microbeads which 
will release cd profoundly after 5 to 6 h after administration, 
therefore microbeads were coated with polymers which mainly 
dissolves in the intestinal pH which will delay the drug release for 5 
to 6 h due to the gastric emptying time of the microbeads. The zero 
order release of the dissolution studies conducted for all the batches 
of coated microbeads are depicted in fig. 7, 8 and 9. The proposed 
mechanism for release along with the n values of microbeads coated 
with acS 100 and acL 100, EC and acL 100, and acE 30D, are shown 
in table 4, 5 and 6 respectively.  
 
 
Fig. 7: Zero order in vitro drug release kinetic studies of 
acL100/acS 100 coated microbeads 
 
 
Fig. 8: Zero order in vitro drug release kinetic studies of EC/acL 
100 coated microbeads 
 
Table 4: Release kinetics of microbeads coated with acS 100 and acL 100 mixtures 
FC   Release kinetics   
Medium Zero-order First order Higuchi Accepted “n-Value” Proposed mechanism for release 
LA1 
 
0.1N HCl 0.783 0.964 0.999 Higuchi 0.234 Anomalous super case I 
7.4 buffer 0.942 0.762 0.944 Higuchi 0.366 Anomalous super case I 
Overall 0.883 0.786 0.893 Higuchi 0.98 Very near to ideal zero order 
LA2 
 
0.1N HCl 0.994 0.999 0.928 First order 0.895 Firstly swelling then diffusion 
7.4 buffer 0.967 0.930 0.972 Higuchi 0.269 Anomalous super case I 
Overall 0.861 0.737 0.962 Higuchi 0.631 Very near to diffusion based 
LA4 0.1N HCl 0.905 0.841 0.983 Higuchi 0.561 Diffusion based release pattern 
7.4 buffer 0.931 0.917 0.961 Higuchi 0.082 Anomalous super case I 
Overall 0.795 0.752 0.954 Higuchi 0.532 Purely diffusion based release 
LA6 0.1N HCl 0.849 0.860 0.930 Higuchi 0.547 Diffusion based release pattern 
7.4 buffer 0.902 0.970 0.925 First order 1.364 Anomalous super case П 
Overall 0.917 0.962 0.879 First order 0.922 Very near to ideal zero order 
LA7 0.1N HCl 0.997 0.954 0.997 unpredictable 0.293 Anomalous super case I 
7.4 buffer 0.663 0.853 0.973 Higuchi 0.689 Firstly swelling then diffusion 
Overall 0.780 0.849 0.900 Higuchi 1.21 Anomalous super case П 
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Table 5: Release kinetics of microbeads coated with EC and acL 100 mixtures 
FC  Release kinetics   
Medium Zero order First order Higuchi Accepted “n-Value” Proposed mechanism for release 
EA1 
 
0.1N HCl 0.843 0.901 0.909 Higuchi 0.178 Anomalous super case I 
7.4 buffer 0.932 0.823 0.940 Higuchi 0.006 Anomalous super case I 
Overall 0.783 0.822 0.911 Higuchi 0.405 Predominantly diffusion based 
EA2 0.1N HCl 0.914 0.943 0.997 Higuchi 0.598 Diffusion based release pattern 
7.4 buffer 0.907 0.921 0.981 Higuchi 0.095 Anomalous super case I 
Overall 0.861 0.893 0.915 Higuchi 0.700 Firstly swelling then diffusion 
EA3 0.1N HCl 0.905 0.841 0.983 Higuchi 0.920 Firstly swelling then diffusion 
7.4 buffer 0.917 0.910 0.972 First order 0.149 Anomalous super case I 
Overall 0.826 0.923 0.910 First order 0.745 Firstly swelling then diffusion 
EA4 0.1N HCl 0.809 0.827 0.960 Higuchi  0.689 Diffusion based release pattern 
7.4 buffer 0.912 0.905 0.970 Higuchi 0.042 Anomalous super case I 
Overall 0.822 0.848 0.932 Higuchi 0.602 diffusion based 
EA5 0.1N HCl 0.928 0.954 0.997 Higuchi 0.100 Anomalous super case I 
7.4 buffer 0.763 0.813 0.983 Higuchi 0.301 Anomalous super case I 
Overall 0.884 0.906 0.932 Higuchi 0.483 Predominantly diffusion based 
 
 
Fig. 9: Zero order in vitro drug release kinetic studies of acE 30D coated micro beads 
 
Table 6: Release kinetics of the microbeads coated with varying percentage of acE 30D 
FC Release kinetics   
Medium Zero order First order Higuchi Accepted “n-Value” Proposed mechanism for release 
AC1 0.1N HCl 0.967 0.980 0.979 First order 0.630 Diffusion based release pattern 
7.4 buffer 0.925 0.935 0.933 First order 0.409 Predominantly Diffusion based 
Overall 0.945 0.968 0.947 First order 0.759 Firstly swelling then diffusion 
AC2 0.1N HCl 0.881 0.896 0.960 Higuchi 0.635 Diffusion based release pattern 
7.4 buffer 0.656 0.762 0.695 First order 0.506 Predominantly diffusion based 
Overall 0.923 0.928 0.897 First order 0.876 Firstly swelling then diffusion 
AC3 
 
0.1N HCl 0.766 0.716 0.621 Zero order 0.861 Firstly swelling then diffusion 
7.4 buffer 0.889 0.890 0.912 Higuchi 0.103 Anomalous super case I 
Overall 0.805 0.824 0.848 Higuchi 0.855 Firstly swelling then diffusion 
AC4 
 
0.1N HCl 0.839 0.853 0.965 Higuchi 0.353 Anomalous super case I 
7.4 buffer 0.836 0.984 0.867 First order 0.968 Very near to zero order release 
Overall 0.936 0.939 0.845 First order 01.041 Anomalous super case П 
 
DISCUSSION 
Characteristic peaks observed in cd after FTIR studies viz. 3443.05 
for-N-H str, 3522.13 for-O-H str (free) 3591.57 for O-H str (bound) 
1629.90 for N-H bending and 1099.46 for-C-O str were also 
observed for the microbeads confirming no interaction between the 
drug and the polymer. Drug entrapment efficiency of the cd 
microbeads was found to be in the range of 64% to 99.52%. The cd 
content of all formulations was good and this may happen due to the 
proper mixing of sodium alginate and drug during mixing using 
mechanical stirrer which didn’t allow the drug to settle down at the 
bottom of the beaker and remain undisclosed. The flow properties of 
the microbeads were found to be good which shows that microbeads 
are non-aggregated. The bulk density and the Carr’s index of 
formulated microbeads were excellent except LA7 and AC1 and 
Hausner’s ratio was good except LA6, LA 7 and AC 4. Swelling 
studies revealed that almost all the microbeads showed maximum 
swelling in alkaline phosphate buffer pH 7.4. The swelling of alginate 
beads in phosphate buffer can be accounted for the exchange of 
Ca2+and Na+. The sodium ions present in phosphate buffer exchange 
with calcium ions, bound to COO-groups of mannuronic blocks.  
Thus, an electrostatic repulsion between negatively charged COO-
groups increases resulting in gel swelling. Exchanged Ca2+ions 
precipitate in the form of insoluble calcium phosphate reflecting in 
slight turbidity of swelling medium. Moisture loss was found to be in 
the range of 0.24% to 7.55%. The lesser proportion of water in the 
microbeads may be attributed to proper drying (before and after 
coating) and instant hardening due to quick gelation occurring 
between calcium chloride and sodium alginate. The microbeads with 
higher moisture content may be due to the involvement of water 
during microbeads formation and hydrophilic property of polymers 
like EC used for coating. 
In vitro dissolution study conducted in subsequently, two media 
showed acS-100 and acL 100 solutions and their combination in 
different ratios exhibited satisfactory results. acL-100 is insoluble in 
gastric pH and soluble from pH 6 and above whereas acS 100 is also 
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gastric insoluble and is soluble from pH 7 and above, in a 
combination of both, the drug release may take place throughout the 
length of intestine and not so much in stomach. Limited drug release 
was seen in almost all the LA coded formulations in acidic medium 
whereas as the release was much higher and faster in alkaline 
medium as the coating dissolved in alkaline surrounding. LA6 
showed 12% drug release in 3 h in an acidic medium and 81% 
overall release in 10 h. Similarly LA4 showed 24% release in 3 h and 
92.43% overall release in the next 7 h. Formulation LA1 though 
releases the drug in similar fashion of LA4 and LA6 in overall 10 h, but 
the release of drug jumped from 20% in 3 h to 68% in 4th hours which 
may cause dose dumping as well as it does not meet our objective of 
releasing the maximum portion of drug after 5 to 6 h. Formulation LA2 
and LA7 showed release of 52% and 53% respectively in 10 h. This 
indicated that higher concentration of acS 100 may interfere with the 
release of drug even in alkaline pH. In batch of microbeads coated with 
acL100 and acS100 polymers, almost all formulations followed timed 
based release pattern and the mechanism of release after comparison 
of R2 values was found to be Higuchi diffusion kinetics which was 
supported by Peppas “n-value”. Only in case of LA6 the overall 
mechanism of release was found to be first order release that is 
concentration depended release.  
The batch of microbeads coated with EC and acL 100 and their 
combination did not match our expectation as much of drug release 
was observed in the acidic medium in the first phase of dissolution 
where according to our objectives, delayed drug release and not 
controlled or sustained release was expected. The first three sets of 
microbeads i.e. EA1, EA2 and EA3 releases drug in the range of 39% 
to 68% in acidic medium and last two ratios i.e. EA4 and EA5 which 
contains higher percentage of EC was capable of delaying the release 
in the acidic medium as they released only 29.71% and 17.92% 
respectively as shown in fig. 8. The basic mechanism for release of 
the drug in this batch mostly was found to be Higuchi with exception 
of EA3 which was found to be first order release. In EA4 and EA5, the 
delayed drug release may have been due to the thick coating of EC 
(3:1 and 2:1) which may have delayed the release as the dissolution 
medium took more time to make pores in the coating thereby 
delaying the drug release from the microbeads.  
The last set of microbeads was coated with different percentage 
(0.4% to 0.7%) of coating solution of acE 30D. The microbeads 
showed good control of release in the first half of dissolution study 
as the drug release was minimum in acidic pH that may be attributed 
to the low permeability of the coating film around the microbeads. 
Though acrylcoat has the property to allow drug to permeate at any 
pH, but it has to first swell and then permeation may happen 
through the pores formed in the coating layer which takes a lag time. 
This delay may have helped out objective of delayed drug release in 
the stomach pH. By the time these microbeads entered the alkaline 
medium, sufficient pores may have formed for drug to diffuse out of 
the microbeads profoundly. The range of release in acidic medium 
was 15% to 27.14% in first 3 h and after these were put in to 
alkaline medium the total drug release in 10 h was found in the 
range of 59.95% to 95.97% as depict in fig. 9. It was also observed 
that higher the concentration of coating solution as in case of AC3 
and AC4, lower the drug release in acidic medium which is in 
accordance with out earlier proposed mechanism of delayed release 
duo to relationship between thickness of coating and time taken for 
pore formation. The mechanism of drug release for most of the 
formulations was found to be first order release with the exception 
of AC3 which showed Higuchi kinetics. According to n value most of 
the formulations showed swelling and diffusion of drug from the 
microbeads with exception of AC4 which showed Anomalous super 
case П transport. Case II transport occurs when the sorption is 
entirely controlled by stress-induced relaxations taking place at a 
sharp boundary separating an outer swollen shell, essentially at 
equilibrium penetrate concentration, from an unpenetrated glassy 
core. Ideally, this sharp boundary moves through the polymer at a 
constant velocity during Case II transport. 
If we compare all the batches of formulations coated with different 
coating materials and their combination, formulation AC3 and AC4 
which was coated with 0.6% and 0.7% of acE 30D showed minimum 
drug release in acidic pH and in alkaline pH release was around 95% 
in 10 h. Although formulation EA4 and EA5 coated with combination 
of ethyl acetate and acL 100 also showed less drug release in acidic 
medium but the overall drug release was also very low in 10 h 
48.92% and 36.71% which may not provide sufficient drug in the 
systematic circulation for showing therapeutic activity. Formulation 
code LA4 and LA6 coated with acL 100 and acS 100 mixture was also 
in line with our objective of delayed drug release as they showed 24 
% and 12.5 % release in acidic medium and overall 92.4% and 
80.89% of drug release. Since the period of observation was 
restricted to 10 h, we were unable to quantify the precise duration of 
release of drug extended antihypertensive efficacy. These 
formulation need to be further studied in respect to other 
parameters and the best formulation may be chosen for invivo 
studies in future. 
CONCLUSION 
Among the 14 formulations designed and evaluated, four 
formulations were in line with our objective of being potentially 
effective dosage form suitable for chronotherapy of early morning 
hypertension and cardiac attacks for which drug products needs to 
be taken at bedtime and able to act in the early morning. But before 
that, further processing parameters needs to be optimized and best-
formulated micro bead need to be taken for in vivo clinical studies in 
suitable dosage form to ascertain its ultimate effectiveness.  
CONFLICT OF INTERESTS 
None 
AUTHORS CONTRIBUTIONS 
All author have contributed equally 
REFERENCES 
1. Bellamy N, Sothern RB, Campbell J. Rhythmic variations in pain 
perception in osteoarthritis of the knee. J Rheumatol 
1990;17:364-72. 
2. Ghosh T, Ghosh A, Kumar A. Chronotherapeutic drug delivery: a 
way forward to treat rhythm guided diseases. J Pharm Sci Res 
2017;9:1894-8. 
3. De Geest BG, Mehuys E, Laekeman G, Demeester J, De Smedt SC. 
Pulsed drug delivery. Expert Opin Drug Delivery 2006;3: 459-62. 
4. Youan BB. Chronopharmaceutics: gimmick or clinically relevant 
approach to drug delivery? J Controlled Release 2004;98:337–53.  
5. Shidhaye SS, Lotlikar VM, Ghule AM, Phutane PK, Kadam VJ. 
Pulsatile delivery systems: an approach for chronotherapeutic 
diseases. Syst Rev Pharm 2010;1:55–61. 
6. Pasic J, Shapiro D, Motivala S, Hui KK. Blood pressure morning 
surge and hostility. Am J Hypertens 1998;11:245–50. 
7. Ura J, Shirachi D, Ferrill M. The chronotherapeutic approach to 
pharmaceutical treatment. California Pharmacist 1992;23: 46-53. 
8. Smolensky MH, Labreque G. Chronotherapeutic. Pharm News 
1997;2:10-6. 
9. Dhalleine C, Assifaoui A, Moulari B, Pellequer Y, Cayot P, Lamprecht 
A, et al. Zinc-pectinate beads as an in vivo self-assembling system 
for pulsatile drug delivery. Int J Pharm 2011;414:28-34. 
10. Kunjachan S, Jose S. Understanding the mechanism of ionic 
gelation for the synthesis of chitosan nanoparticles using 
qualitative techniques. Asian J Pharm 2010;4:148-3. 
11. Mattam J, Sailaja K. Preparation and evaluation of sulfasalazine 
loaded sodium alginate microbeads for sustained 
delivery. Asian J Pharma Clin Res 2016;9:72-6. 
12. Andrea C, Giulia A, Pasquale DG, Francesca S, Rita PA, Paola R. 
Novel core-shell chronotherapeutic system for the oral 
administration of ketoprofen. J Drug Delivery Sci Technol 
2016;32:126-31. 
13. Mazumder R, Nath LK, Haque A, Maity T, Choudhury PK, 
Shrestha B, et al. Formulation and in vitro evaluation of natural 
polymers based microspheres for colonic drug delivery. Int J 
Pharm Pharm Sci 2010;2:211-9. 
14. Girhepunje KM, Piillai K, Pal RS, Gevariya HB, Thirumoorthy N. 
Celecoxib loaded microbeads: a targeted drug delivery for 
colorectal cancer. Int J Curr Pharma Res 2010;2:46-55. 
Ghosh et al. 
Int J App Pharm, Vol 10, Issue 3, 2018, 92-99 
 
99 
15. Saparia B, Murthy RSR, Solanki. Preparation and evaluation of 
chlorquine phosphate microspheres using cross-linked gelatin 
for long-term drug delivery. Indian J Pharm Sci 2002;64:48-52. 
16. Sangeetha S, Sakthisaravanan V, Komala M, Harish G, Sivakumar V. 
Design and evaluation of gastro retentive beads of theophylline by 
Ionotropic gelation. Int J Pharm Pharm Sci 2010;2:99-101. 
17. Ghosh A, Biswas S, Ghosh T. Preparation and evaluation of 
silymarin β-cyclodextrin Molecular inclusion complexes. J 
Young Pharmacists 2011;3:205-10. 
18. GN Vishal, Gowda D, Balamuralidhara V, Khan SM. Formulation 
and evaluation of olanzapine matrix pellets for controlled 
release. Daru 2011;19:249-56. 
19. Lachman L, Lieberman HA. Joseph LK. editors. The theory and 
practice of industrial pharmacy. 3rd Edition. Philadelphia: Lea 
and Febiger; 1986.  
20. Ghosh A, Saha A, Das S, Ghosh T. Formulation and in vitro 
evaluation of zidovudine loaded E C microcapsules. Int J 
Pharma Sci Res 2011;2:289-97.  
21. Varshosaz J, Jaffarian A, Golafshan S. Colon-specific delivery of 
mesalazine chitosan microspheres. J Microencapsulation 
2006;23:329-39. 
22. Dandagi PM, Mastihomath VS, Patil MB, Manvi FV, Gadad AP, 
Sharma R. Development and evaluation of theophyllin and 
salbutamol sulphate sustained release matrix tablets. Indian J 
Pharm Sci 2005;67:598-602. 
 
